Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Jennifer Guimbellot

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
Address4301 W Markham
Little Rock AR 72205
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Rose NR, Dabbs SG, O'Hagan EC, Guimbellot JS. Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review. Pediatr Pulmonol. 2024 Aug 21. PMID: 39166713.
      View in: PubMed
    2. Baker E, Harris WT, Guimbellot JS, Bliton K, Rowe SM, Raju SV, Oates GR. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL). J Cyst Fibros. 2024 Sep; 23(5):959-966. PMID: 39033068.
      View in: PubMed
    3. Liu Z, Anderson JD, Rose NR, Baker EH, Dowell AE, Ryan KJ, Acosta EP, Guimbellot JS. Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia. Pulm Pharmacol Ther. 2024 Sep; 86:102314. PMID: 38964603.
      View in: PubMed
    4. Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024 Sep; 86:102301. PMID: 38797221.
      View in: PubMed
    5. Li C, Liu Z, Anderson J, Liu Z, Tang L, Li Y, Peng N, Chen J, Liu X, Fu L, Townes TM, Rowe SM, Bedwell DM, Guimbellot J, Zhao R. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells. PLoS One. 2023; 18(11):e0295009. PMID: 38019847.
      View in: PubMed
    6. Young D, Bartlett LE, Guimbellot J, Milinic T, Burdis N, Gill ER, Lease ED, Goss CH, Kapnadak SG, Ramos KJ. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant. J Cyst Fibros. 2024 May; 23(3):545-548. PMID: 37798159.
      View in: PubMed
    7. Oates GR, Mims C, Geurs R, Bergquist R, Hager A, Guimbellot JS, Hartzes AM, Gutierrez HH. Mobile health platform for self-management of pediatric cystic fibrosis: Impact on patient-centered care outcomes. J Cyst Fibros. 2023 09; 22(5):823-829. PMID: 37085386.
      View in: PubMed
    8. Gunnett MA, Baker E, Mims C, Self ST, Gutierrez HH, Guimbellot JS. Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome. Front Pediatr. 2023; 11:1127659. PMID: 36969284.
      View in: PubMed
    9. Anderson JD, Davis BH, Giang G, Jones A, Lee CR, Parker K, Searcy H, Benner K, Limdi NA, Guimbellot JS. Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis. Clin Transl Sci. 2023 04; 16(4):662-672. PMID: 36760155.
      View in: PubMed
    10. Oates GR, Lock L, Tarn V, Geurs R, Guimbellot JS, Baker E, Magruder T. Electronic screening for unmet social needs in a pediatric pulmonary clinic: Acceptability and associations with health outcomes. Pediatr Pulmonol. 2023 05; 58(5):1444-1453. PMID: 36721912.
      View in: PubMed
    11. Guimbellot JS, Nichols DP, Brewington JJ. Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis. Clin Chest Med. 2022 12; 43(4):617-630. PMID: 36344070.
      View in: PubMed
    12. Ryan KJ, Guimbellot JS, Dowell AE, Reed-Walker KD, Kerstner-Wood CD, Anderson JD, Liu Z, Acosta EP. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Dec 15; 1213:123518. PMID: 36371965.
      View in: PubMed
    13. Guimbellot JS, Ryan KJ, Anderson JD, Parker KL, Victoria Odom L, Rowe SM, Acosta EP. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis. Pediatr Pulmonol. 2022 11; 57(11):2745-2753. PMID: 35927224.
      View in: PubMed
    14. Ramos KJ, Guimbellot JS, Valapour M, Bartlett LE, Wai TH, Goss CH, Pilewski JM, Faro A, Diamond JM. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients. J Cyst Fibros. 2022 09; 21(5):745-752. PMID: 35474016.
      View in: PubMed
    15. Liu Z, Anderson JD, Natt J, Guimbellot JS. Culture and Imaging of Human Nasal Epithelial Organoids. J Vis Exp. 2021 12 17; (178). PMID: 34978285.
      View in: PubMed
    16. Smith M, Ryan KJ, Gutierrez H, Sanchez LHG, Anderson JN, Acosta EP, Benner KW, Guimbellot JS. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. J Cyst Fibros. 2022 01; 21(1):e8-e10. PMID: 34130909.
      View in: PubMed
    17. Anderson JD, Liu Z, Odom LV, Kersh L, Guimbellot JS. CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling. Am J Physiol Lung Cell Mol Physiol. 2021 07 01; 321(1):L119-L129. PMID: 34009038.
      View in: PubMed
    18. Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med. 2021 07; 9(7):677-679. PMID: 33965001.
      View in: PubMed
    19. Guimbellot JS, Baines A, Paynter A, Heltshe SL, VanDalfsen J, Jain M, Rowe SM, Sagel SD. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. J Cyst Fibros. 2021 03; 20(2):213-219. PMID: 33249004.
      View in: PubMed
    20. Hoppe JE, Guimbellot J, Martiniano SL, Toprak D, Davis C, Daines CL, Muhlebach MS, Esther CR, Dellon EP. Highlights from the 2019 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2020 09; 55(9):2225-2232. PMID: 32573948.
      View in: PubMed
    21. Liu Z, Anderson JD, Deng L, Mackay S, Bailey J, Kersh L, Rowe SM, Guimbellot JS. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis. Genes (Basel). 2020 05 29; 11(6). PMID: 32485957.
      View in: PubMed
    22. Secunda KE, Guimbellot JS, Jovanovic B, Heltshe SL, Sagel SD, Rowe SM, Jain M. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. Am J Respir Crit Care Med. 2020 04 15; 201(8):996-998. PMID: 31841644.
      View in: PubMed
    23. Guimbellot JS, Ryan KJ, Anderson JD, Liu Z, Kersh L, Esther CR, Rowe SM, Acosta EP. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. J Cyst Fibros. 2020 09; 19(5):742-745. PMID: 32044246.
      View in: PubMed
    24. Liu Z, Mackay S, Gordon DM, Anderson JD, Haithcock DW, Garson CJ, Tearney GJ, Solomon GM, Pant K, Prabhakarpandian B, Rowe SM, Guimbellot JS. Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging. Biomed Opt Express. 2019 Oct 01; 10(10):5414-5430. PMID: 31646055.
      View in: PubMed
    25. Sanders CD, Guimbellot JS, Muhlebach MS, Lin FC, Gilligan P, Esther CR. Tracheostomy in children: Epidemiology and clinical outcomes. Pediatr Pulmonol. 2018 09; 53(9):1269-1275. PMID: 29968973.
      View in: PubMed
    26. Poore TS, Virella-Lowell I, Guimbellot JS. Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatr Pulmonol. 2018 07; 53(7):E21-E23. PMID: 29790674.
      View in: PubMed
    27. Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019 01; 18(1):102-109. PMID: 29685811.
      View in: PubMed
    28. Guimbellot JS, Acosta EP, Rowe SM. Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 05; 53(5):E6-E8. PMID: 29488691.
      View in: PubMed
    29. Guimbellot JS, Leach JM, Chaudhry IG, Quinney NL, Boyles SE, Chua M, Aban I, Jaspers I, Gentzsch M. Nasospheroids permit measurements of CFTR-dependent fluid transport. JCI Insight. 2017 11 16; 2(22). PMID: 29202459.
      View in: PubMed
    30. Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017 Nov; 52(S48):S4-S14. PMID: 28881097.
      View in: PubMed
    31. Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ, Hong JS. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics. 2009 Mar 25; 2:15. PMID: 19320992.
      View in: PubMed
    32. Guimbellot JS, Fortenberry JA, Siegal GP, Moore B, Wen H, Venglarik C, Chen YF, Oparil S, Sorscher EJ, Hong JS. Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol. 2008 Nov; 39(5):514-21. PMID: 18474670.
      View in: PubMed
    33. Varga K, Jurkuvenaite A, Wakefield J, Hong JS, Guimbellot JS, Venglarik CJ, Niraj A, Mazur M, Sorscher EJ, Collawn JF, Beb?k Z. Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J Biol Chem. 2004 May 21; 279(21):22578-84. PMID: 15066992.
      View in: PubMed
    34. Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res. 2003 Nov 01; 290(2):414-9. PMID: 14567998.
      View in: PubMed
    Guimbellot's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (148) concept(s)
    _
    Similar People Expand Description
    See all (36) people
    _
    Same Department Expand Description
    Search Department